CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
13 janv. 2025 08h00 HE
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense...
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
07 janv. 2025 16h05 HE
|
CAMP4 Therapeutics
Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two...
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
10 déc. 2024 08h00 HE
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting...
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
02 déc. 2024 08h00 HE
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting...
CAMP4 Reports Third Quarter 2024 Financial Results
21 nov. 2024 16h05 HE
|
CAMP4 Therapeutics
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in...
CAMP4 Announces Pricing of Initial Public Offering
10 oct. 2024 19h07 HE
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting...
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
21 mars 2024 07h58 HE
|
CAMP4 Therapeutics
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D